{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:21:28Z","timestamp":1790029288318,"version":"4.0.1"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Price reductions for originator biologics with biosimilar competitors have been modest in the US. This may be due to the US reimbursement model, where clinicians or their employing medical institution receive payment based on the percentage of the cost billed, incentivizing the highest-cost product. Currently, US policymakers are debating changing this policy. However, a clear understanding of price reductions achieved by the current system is needed to inform future reform efforts.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the associations of biosimilar entry with the prices of originator biologics under Medicare Part B reimbursement.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used bayesian structural time series models to analyze Medicare Part B Drug average sales price (ASP) data from quarter 1 of 2005 to quarter 1 of 2025, including 7 biologics with biosimilars available for at least 3 years (bevacizumab, epoetin, filgrastim, infliximab, pegfilgrastim, rituximab, and trastuzumab).<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Biosimilar entry.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Relative differences in observed ASPs for originators and biosimilars vs the bayesian structural time series\u2013estimated counterfactual ASPs for originators had biosimilars not entered the market.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Analysis included 7 originator biologics that entered the market between 1989 and 2024. The number of biosimilars marketed during the study period ranged between 1 and 6 for originator biologics studied. Biosimilar entry was associated with changes in the ASP of the originator biologic of \u22127.4% (95% prediction interval, \u201310.5% to \u22124.3%) at 1 year, \u221231.7% (95% prediction interval, \u201341.6% to \u221221.9%) at 3 years, and \u221243.1% (95% prediction interval, \u201361.3% to \u221224.8%) at 5 years. Savings varied by drug, with the largest price reductions observed with pegfilgrastim and infliximab, with 5-year price reductions of \u221282.0% (95% prediction interval, \u201395.2% to \u221254.0%) for pegfilgrastim and \u221262.3% (95% prediction interval, \u201373.4% to \u221245.2%) for infliximab. Biosimilar prices were generally lower than the originator biologics at all postentry periods and decreased over time.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, counterfactual analysis found that price reductions from biosimilar entry were more substantial than suggested by simpler pre-post comparisons. However, these savings remained less than those achieved by small-molecule generics, highlighting the need for policy reforms to enhance market competition and realize greater savings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.42937","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:00:16Z","timestamp":1762876816000},"page":"e2542937","source":"Crossref","is-referenced-by-count":9,"title":["Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market"],"prefix":"10.1001","volume":"8","author":[{"given":"Abdullah","family":"Abdelaziz","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron N.","family":"Winn","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Vanderbilt Ingram Cancer Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"8","key":"zoi251167r1","first-page":"469","article-title":"The economics of biosimilars.","volume":"6","author":"Blackstone","year":"2013","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"zoi251167r3","first-page":"3","article-title":"Biosimilar cost savings in the united states: initial experience and future potential.","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"},{"issue":"12","key":"zoi251167r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44670","article-title":"Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland.","volume":"5","author":"Carl","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi251167r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33451","article-title":"Association of generic competition with price decreases in physician-administered drugs and estimated price decreases for biosimilar competition.","volume":"4","author":"Dickson","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi251167r8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jval.2019.12.007","article-title":"Biosimilar uptake in Medicare Part B varied across hospital outpatient departments and physician practices: the case of filgrastim.","volume":"23","author":"Socal","year":"2020","journal-title":"Value Health"},{"issue":"6","key":"zoi251167r9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamaoncol.2018.6196","article-title":"Association between reimbursement incentives and physician practice in oncology: a systematic review.","volume":"5","author":"Mitchell","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi251167r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.4335","article-title":"Biosimilar uptake in Medicare Advantage vs traditional Medicare.","volume":"4","author":"Kozlowski","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"1","key":"zoi251167r11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18553\/jmcp.2024.30.1.15","article-title":"Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with traditional Medicare, 2016-2019.","volume":"30","author":"Liu","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"20","key":"zoi251167r12","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1200\/JCO-24-01907","article-title":"Use of low-value cancer treatments in Medicare Advantage versus traditional Medicare.","volume":"43","author":"Jung","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi251167r13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1377\/hlthaff.2022.00812","article-title":"The role of financial incentives in biosimilar uptake in Medicare: evidence from the 340B program.","volume":"42","author":"Bond","year":"2023","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi251167r14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40258-023-00812-w","article-title":"What about offering a financial incentive directly to clinical units to encourage the use of biosimilars? results of a two-year national experiment in France.","volume":"21","author":"Tano","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"zoi251167r15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312577","author":"Itoshima","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"zoi251167r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429","article-title":"Patient out-of-pocket costs for biologic drugs after biosimilar competition.","volume":"5","author":"Feng","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"8","key":"zoi251167r17","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1001\/amajethics.2019.668","article-title":"Why are biosimilars not living up to their promise in the US?","volume":"21","author":"Zhai","year":"2019","journal-title":"AMA J Ethics"},{"issue":"1","key":"zoi251167r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34776","article-title":"Physician, practice, and patient characteristics associated with biosimilar use in Medicare recipients.","volume":"4","author":"Dean","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi251167r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.2634","article-title":"Changes in Medicare Part B spending for biologic drugs after biosimilar entry into the market.","volume":"2","author":"Dean","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"490","key":"zoi251167r22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1198\/jasa.2009.ap08746","article-title":"Synthetic control methods for comparative case studies: estimating the effect of California\u2019s tobacco control program.","volume":"105","author":"Abadie","year":"2010","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"zoi251167r23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1214\/14-AOAS788","article-title":"Inferring causal impact using bayesian structural time-series models.","volume":"9","author":"Brodersen","year":"2015","journal-title":"Ann Appl Stat"},{"issue":"1","key":"zoi251167r24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","article-title":"Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition.","volume":"42","author":"Michaeli","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"zoi251167r25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1470-2045(22)00073-0","article-title":"Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.","volume":"23","author":"Vokinger","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi251167r26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States.","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi251167r28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi251167r34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/hec.4471","article-title":"Biosimilar competition: Early learning.","volume":"31","author":"Frank","year":"2022","journal-title":"Health Econ"},{"issue":"3","key":"zoi251167r36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40259-021-00479-6","article-title":"Physician understanding and willingness to prescribe biosimilars: findings from a US national survey.","volume":"35","author":"Kolbe","year":"2021","journal-title":"BioDrugs"},{"key":"zoi251167r31","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"zoi251167r2","unstructured":"Biosimilars in the United States 2023-2027: competition, savings, and sustainability. IQVIA. January 31, 2023. Accessed April 23, 2025. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/biosimilars-in-the-united-states-2023-2027"},{"key":"zoi251167r4","unstructured":"Biological product innovation and competition. US Food and Drug Administration. Published online April 9, 2024. Accessed May 20, 2025. https:\/\/www.fda.gov\/drugs\/biosimilars\/biological-product-innovation-and-competition"},{"key":"zoi251167r6","unstructured":"Arad? N, Lopez? MH, Ray? R, . Realizing the benefits of biosimilars: what the U.S. can learn from Europe. Duke Margolis Institute for Health Policy. April 28, 2021. Accessed May 20, 2025. https:\/\/healthpolicy.duke.edu\/publications\/realizing-benefits-biosimilars-what-us-can-learn-europe"},{"key":"zoi251167r19","unstructured":"Data snapshot: biosimilar cost and use trends in Medicare Part B. Office of the Inspector General, U.S. Department of Health and Human Services. Published online March 6, 2024. Accessed May 20, 2025. https:\/\/oig.hhs.gov\/reports\/all\/2024\/data-snapshot-biosimilar-cost-and-use-trends-in-medicare-part-b\/"},{"key":"zoi251167r20","unstructured":"Maxwell A. Biosimilars have lowered costs for Medicare Part B and enrollees, but opportunities for substantial spending reductions still exist. U.S. Department of Health and Human Services. Published online September 27, 2023. Accessed September 15, 2024. https:\/\/oig.hhs.gov\/reports\/all\/2023\/biosimilars-have-lowered-costs-for-medicare-part-b-and-enrollees-but-opportunities-for-substantial-spending-reductions-still-exist\/"},{"key":"zoi251167r27","unstructured":"Medicare Part B drug average sales price. Centers for Medicare & Medicaid Services. Published online 2024. Accessed January 5, 2025. https:\/\/www.cms.gov\/medicare\/payment\/fee-for-service-providers\/part-b-drugs\/average-drug-sales-price"},{"key":"zoi251167r29","unstructured":"Inflation Reduction Act of 2022, HR 5376, 117th Cong (2021-2022). Pub L No. 117-169. Accessed May 20, 2025. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text"},{"key":"zoi251167r30","unstructured":"Purple Book database of Licensed Biological Products. US Food and Drug Administration. Accessed October 1, 2025. https:\/\/purplebooksearch.fda.gov\/"},{"key":"zoi251167r32","unstructured":"Consumer Price Index for all urban consumers: medical care in U.S. city average (CPIMEDSL). Federal Reserve Bank of St Louis. Published online 2024. Accessed September 15, 2024. https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL"},{"key":"zoi251167r33","unstructured":"Medicare Part B enrollee use and spending on biosimilars. Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. January 15, 2025. Accessed May 20, 2025. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/be065dbbd1f866c65cf627995bd2ea56\/biosimilars-medicare-part-b.pdf"},{"key":"zoi251167r35","unstructured":"Conrad? R, Davis? K. Estimating cost savings from new generic drug approvals in 2021. Center for Drug Evaluation and Research, U.S. Food & Drug Administration. 2023. Accessed April 15, 2025. https:\/\/www.fda.gov\/media\/172608\/download?attachment"},{"key":"zoi251167r37","unstructured":"Part B drugs payment systems. Medicare Payment Advisory Commission. 2024. Accessed May 20, 2025. https:\/\/www.medpac.gov\/wp-content\/uploads\/2024\/10\/MedPAC_Payment_Basics_24_PartB_FINAL_SEC.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2841238\/abdelaziz_2025_oi_251167_1762278929.14337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:00:26Z","timestamp":1762876826000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2841238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.42937","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}